.png){kind=icon}
.png){kind=icon}
Return
Prescription of Targeted Therapies in patient with a history of cancer
.png){kind=icon}
OA
AI
E
J
DOI：10.1016/j.jbspin.2026.106068.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Chronic inflammation inherent to inflammatory arthritis is a major driver of cancer risk, underscoring the importance of effective disease control. • In patients without prior malignancy, most targeted therapies do not increase overall cancer risk, although caution is warranted with JAK inhibitors and abatacept. • Observational data show no increased risk of new or recurrent cancer with TNF inhibitors compared with conventional DMARDs in patients with a history of solid tumors. • Initiation of TNF inhibitors within five years after cancer diagnosis is not associated with higher cancer recurrence or mortality. • Evidence for other targeted therapies in patients with prior cancer remains limited, highlighting important knowledge gaps. • The 2024 EULAR Points to Consider support individualized, multidisciplinary decision-making without a mandatory waiting period after cancer remission. • Future research must address long-term safety of newer targeted therapies and develop personalized cancer risk stratification tools for patients with inflammatory arthritis.
Keywords:
inflammatory arthritis
cancer risk
targeted therapies
TNF inhibitors
JAK inhibitors
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.3
Papers:
4.2K
Citations:
4.8K
Organization
No organization information available
Cited Papers